News

Bel Fuse Inc. Declares Quarterly Dividends on Class Shares

Bel Fuse Inc. Declares Quarterly Dividends on Class Shares

Bel Fuse Inc. Declares Regular Cash Dividends

Bel Fuse Inc., recognized for its innovative electronic solutions, recently announced the declaration of regular quarterly cash dividends. The Board of Directors has approved a dividend of $0.06 per share for the Class A common shares and $0.07 per share for Class B common shares. This decision highlights the company’s dedication to rewarding its shareholders and reflects its ongoing strength in the competitive market of electronic components.

Details on Dividend Payments and Record Dates

These cash dividends for both Class A and Class B common shares are scheduled to be paid on January 31, 2025. Shareholders must be on record by January 15, 2025, to be eligible for the upcoming payment. This strategic move not only supports current investors but also underlines Bel Fuse's solid financial health and growth trajectory.

Overview of Bel Fuse Inc.

With nearly 12.5 million common shares outstanding, the composition includes approximately 2.1 million Class A shares and about 10.4 million Class B shares. Bel Fuse continues to enhance its reputation by offering a diverse portfolio of products that plays a crucial role in powering, protecting, and connecting electronic circuits globally. Their offerings cater to various industries such as telecommunications, military, aerospace, and even automotive sectors, showcasing the versatility and wide-reaching impact of their technologies.

Innovative Product Lines from Bel

Bel Fuse’s product categories are extensive. The company is committed to designing and manufacturing solutions that include Magnetic Solutions, Power Solutions, and Connectivity Solutions. Products like integrated connector modules and circuit protection devices play a significant role in various applications, from data transmission to consumer electronics. This dedication to product innovation and quality has positioned Bel Fuse as a leader in the market.

Commitment to Shareholder Value

The recent dividend announcements serve as an affirmation of Bel Fuse Inc.'s commitment to delivering shareholder value. This strategy not only fosters investor confidence but also signals the company’s robust business model. As they continue to grow and adapt to market needs, maintaining a consistent dividend policy helps solidify a trustworthy image in the eyes of their investors.

Contact Information

Investors seeking further information can contact Steven Hooser or Jean Marie Young at Three Part Advisors, LLC, by calling (631) 418-4339. For inquiries related to financial reporting, Lynn Hutkin, the Vice President of Financial Reporting and Investor Relations, is available via email at ir@belf.com.

Frequently Asked Questions

What are the declared dividends for Bel Fuse Inc.?

The declared dividends are $0.06 for Class A shares and $0.07 for Class B shares.

When will the dividends be paid?

The dividends are set to be paid on January 31, 2025.

Who is eligible for the dividend payment?

Investors who are shareholders on record as of January 15, 2025, will be eligible for the dividend payment.

How does Bel Fuse contribute to multiple industries?

Bel Fuse provides products used in telecommunications, military, and automotive sectors among others, showcasing its versatility.

How can investors contact Bel Fuse for more information?

Investors can contact Steven Hooser or Jean Marie Young at (631) 418-4339 or email Lynn Hutkin at ir@belf.com.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Innovent's SINTBILO® Hits Primary Endpoint in Study

Updated Category News Views 234

Innovent's Latest Breakthrough with SINTBILO® One moment you're sipping coffee, the next you're staring at a clinical milestone. Innovent Biologics has shouted from the rooftops that their drug, SINTBILO® (tafolecimab injection), has wrapped up its Phase 3 CREDIT-5 study, snagging the primary endpoint with both hands. This isn't just any drug; it's marked as the first...

Continue Reading
Xiaomi's Smart Auto Factory Draws Global Media Praise

Updated Category News Views 178

Xiaomi Impresses Global Media in Beijing Factory Tour In the ever-changing world of NEVs (New Energy Vehicles), a tour of Xiaomi's smart auto factory in Beijing has made waves among global media folks. These scribes got an up-close look at Xiaomi's magic mix of tech and style on November 6, part of a grand media gathering. What's Under the Hood? Marcos Costa de Oliveira,...

Continue Reading
Photocure Navigates AssureMDx's Medicare Journey

Updated Category News Views 70

Aiming High with AssureMDx Photocure's got this bladder cancer test called AssureMDx that's at the center of its recent moves after acquiring Vesica Health a few months back. This isn't just any test; it's a urine-based, non-invasive way to snag an early look at bladder cancer. With the FDA's Breakthrough Device tag pinned on, they're not just dipping their toes in—this...

Continue Reading
Valmet Expands Board Maker Deal in Asia With New Line

Updated Category News Views 115

If there's one thing Valmet understands, it's the beauty of a longstanding business relationship. On November 9, 2026, the Finnish powerhouse announced another feather in its cap—a new board making line order from a major client in Asia. This deal ain't just another tick in the order books. No, sir, it's about prowess and power in the paper game. Building on Existing...

Continue Reading
Strathcona Resources Q3 2026: Dividends, Deals, and Growth

Updated Category News Views 202

Digging into Strathcona's Third Quarter Strathcona Resources (TSX: SCR) is strutting its stuff again, dropping a third-quarter report that reads like a playbook for solid energy sector performance. First off, let’s talk about that dividend bump. The company decided to sprinkle some cheer with a 7% increase in its quarterly dividend, now at $0.32 per share. Not exactly...

Continue Reading
Telespazio & Rivada Forge Secure Satellite Network

Updated Category News Views 0

Rivada's Outernet: A New Era of Connectivity Forget the terrestrial wires; we're talking about 600 satellites playing a space-age game of telephone. That's Rivada's Outernet for you, an orbital mesh network that's about to upend the very nature of global communications. Telespazio's new partnership with Rivada is like strapping a rocket onto secure connectivity in the...

Continue Reading
Korean 'Glocal' Districts Entice U.S. Tourists with Local Flavor

Updated Category News Views 97

Gwangju's Dongmyeong-dong is like the neighborhood artists and hipsters flock to in New York—except it’s got a Korean twist. Nestled in the Jeonnam region, this place is hot on American tourists' radar for its spicy mix of local culture, unique eats, and shops that scream individuality. It's becoming a magnet for folks who want to get a taste of Korean life but with a...

Continue Reading
CureGene's Evategrel Aims for Breakthrough in Stroke Care

Updated Category News Views 172

Revolutionizing Stroke Care: Enter Evategrel When it comes to strokes, time is money—and I'm telling you, this ain't an area where you can afford to twiddle your thumbs. The faster you can get that blood flowing again, the better the chance you've got of walking away with less damage. That's where CureGene's new investigational drug, Evategrel, comes in. Why Evategrel...

Continue Reading
SpaceMap Tackles Space Traffic With AI Innovation

Updated Category News Views 0

SpaceMap Takes Aim at the Crowded Space Above You ever look up and wonder what's hurtling above our noggins? More satellites than you can shake a stick at, that's what. And don't even start me on the debris floating around. This ain't just rocket science anymore; it's a crowded dance floor, and someone's gotta manage it. Enter SpaceMap, a plucky South Korean startup that...

Continue Reading
UAE Pioneers eATA Carnet System Beyond Europe

Updated Category News Views 56

Breaking Tradition with Digital Innovation Well, who would’ve thought? The UAE just leapt ahead in the trade game, becoming the first to roll out the eATA Carnet system beyond the cozy confines of Europe. This isn’t some run-of-the-mill tech rollout, folks. It’s a digital revolution in how temporary imports are handled—goodbye paper, hello efficiency! With this...

Continue Reading

Top 5 Most Recently Viewed Articles

Disney Postpones Asia Cruise Ship Launch Amid Challenges

Updated Category News Views 232

Disney Delays Launch of Its First Asia Cruise Ship Walt Disney Co. (NYSE: DIS) has announced a three-month delay in the inaugural voyage of its first Asia-based cruise ship, the Disney Adventure. Originally set to embark from Singapore on December 15, the new launch date is now March 10, 2026, due to unexpected setbacks in the shipbuilding process. Challenges in...

Continue Reading
Promising Outcomes from ASPIRO Phase 1/2a Trial for Parkinson's

Updated Category News Views 159

Promising Results from Aspen Neuroscience's Clinical Study Aspen Neuroscience has recently shared encouraging insights from the ASPIRO Phase 1/2a clinical trial, focusing on their innovative cell therapy, ANPD001, aimed at treating Parkinson's Disease. This investigational approach leverages autologous dopaminergic neuronal precursor cells (DANPC) that hold the potential...

Continue Reading
Exploring Honeywell Intl's Options Trends and Market Analysis

Updated Category News Views 213

Understanding Honeywell Intl's Current Options Landscape The dynamic environment of finance recently showcased an intriguing shift with notable bearish movements concerning Honeywell Intl. The latest analysis of options trading data for Honeywell Intl (HON) has spotlighted a total of 10 unique trades that have piqued interest among traders. In an examination of the...

Continue Reading
Transforming Business with Google Agentspace and Premier Cloud

Updated Category News Views 217

Transforming Business with Google Agentspace and Premier Cloud Premier Cloud has been recognized as a launch partner for Google Agentspace, Google's innovative new AI platform that aims to revolutionize enterprise search and productivity. This partnership is a significant milestone for Premier Cloud, a prominent Google Cloud Premier Partner, renowned for its expertise in...

Continue Reading
Transforming Biotechnology: A New Era for Advanced Therapies

Updated Category News Views 156

Innovative Biomanufacturing Comes to Saudi Arabia At the forefront of a new biotechnology initiative, a strategic partnership has emerged between King Faisal Specialist Hospital & Research Centre (KFSHRC) and Germfree Laboratories, LLC, unveiling a state-of-the-art Advanced Therapy Medicinal Product (ATMP) Manufacturing Campus. This exciting development represents a...

Continue Reading